论文信息 - Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement

Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement

Department of Cardiac, Thoracic and Vascular Sciences, University of Padova Medical School, Via N. Giustiniani 2, Padova 35121, Italy; Heart Center Osnabrück-Bad Rothenfelde, Marienhospital Osnabrück, Osnabrück, Germany; New England Cardiac Arrhythmia Center, Tufts University School of Medicine, Boston, MA, USA; ICIN-Netherlands Heart Institute, Utrecht, The Netherlands; University of Pennsylvania Health System, Philadelphia, PA, USA; First Cardiology Department, University of Athens, Medical School, Athens, Greece; Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland; Yannis Protonotarios Medical Centre, Hora Naxos, Greece; Johns Hopkins Hospital, Baltimore, MD, USA; University Hospital of Münster, Münster, Germany; Center of Sports Sciences, Rome, Italy; The Heart Hospital, London, UK; and University of Arizona, Tucson, USA

[1] T. Edvardsen,et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members , 2014, European journal of heart failure.

[2] F. Marchlinski,et al. Ventricular tachycardia mapping and ablation in arrhythmogenic right ventricular cardiomyopathy/dysplasia: Lessons Learned. , 2014, World journal of cardiology.

[3] L. Mestroni,et al. Titin and desmosomal genes in the natural history of arrhythmogenic right ventricular cardiomyopathy , 2014, Journal of Medical Genetics.

[4] M. Link,et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. , 2014, Journal of the American College of Cardiology.

[5] L. Held,et al. Usefulness of electrocardiographic parameters for risk prediction in arrhythmogenic right ventricular dysplasia. , 2014, The American journal of cardiology.

[6] S. Priori,et al. Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate With a Brugada Syndrome Phenotype , 2014, Circulation.

[7] L. Held,et al. Different Prognostic Value of Functional Right Ventricular Parameters in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2014, Circulation. Cardiovascular imaging.

[8] D. Corrado,et al. Compound and Digenic Heterozygosity Predicts Lifetime Arrhythmic Outcome and Sudden Cardiac Death in Desmosomal Gene–Related Arrhythmogenic Right Ventricular Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[9] Stefan L. Zimmerman,et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. , 2013, Journal of the American College of Cardiology.

[10] C. Semsarian,et al. Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. , 2013, International journal of cardiology.

[11] S. Russell,et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. , 2013, Journal of the American College of Cardiology.

[12] A. Schinkel. Implantable Cardioverter Defibrillators in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Patient Outcomes, Incidence of Appropriate and Inappropriate Interventions, and Complications , 2013, Circulation. Arrhythmia and electrophysiology.

[13] D. Corrado,et al. Prognostic Value of Endocardial Voltage Mapping in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2013, Circulation. Arrhythmia and electrophysiology.

[14] L. Held,et al. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. , 2013, The American journal of cardiology.

[15] S. Russell,et al. Risk Stratification in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy–Associated Desmosomal Mutation Carriers , 2012, Circulation. Arrhythmia and electrophysiology.

[16] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[17] Wojciech Zareba,et al. Reduction in inappropriate therapy and mortality through ICD programming. , 2012, The New England journal of medicine.

[18] R. Hauer,et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.

[19] P. Kirchhof,et al. Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. , 2012, Progress in biophysics and molecular biology.

[20] T. Lüscher,et al. Predictors of Appropriate ICD Therapy in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy: Long Term Experience of a Tertiary Care Center , 2012, PloS one.

[21] S. Rizzo,et al. Intercalated disc abnormalities, reduced Na(+) current density, and conduction slowing in desmoglein-2 mutant mice prior to cardiomyopathic changes. , 2012, Cardiovascular research.

[22] S. Themistoclakis,et al. Fragmented and delayed electrograms within fibrofatty scar predict arrhythmic events in arrhythmogenic right ventricular cardiomyopathy: results from a prospective risk stratification study. , 2012, Heart rhythm.

[23] M. Ackerman,et al. Videoscopic Left Cardiac Sympathetic Denervation for Patients With Recurrent Ventricular Fibrillation/Malignant Ventricular Arrhythmia Syndromes Besides Congenital Long-QT Syndrome , 2012, Circulation. Arrhythmia and electrophysiology.

[24] S. Russell,et al. Outcomes of Catheter Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2012, Circulation. Arrhythmia and electrophysiology.

[25] P. Vardas,et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia and troponin release. Myocarditis or the "hot phase" of the disease? , 2012, International journal of cardiology.

[26] F. Liang,et al. Connexin43 and the regulation of intercalated disc function. , 2012, Heart rhythm.

[27] D. Corrado,et al. Pathophysiology of arrhythmogenic cardiomyopathy , 2012, Nature Reviews Cardiology.

[28] D. Corrado,et al. Imaging Study of Ventricular Scar in Arrhythmogenic Right Ventricular Cardiomyopathy: Comparison of 3D Standard Electroanatomical Voltage Mapping and Contrast-Enhanced Cardiac Magnetic Resonance , 2012, Circulation. Arrhythmia and electrophysiology.

[29] J. Brugada,et al. Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique , 2012, Circulation. Arrhythmia and electrophysiology.

[30] S. Russell,et al. Cardiac transplantation in arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2012, Journal of the American College of Cardiology.

[31] P. Lambiase,et al. Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study , 2012, European heart journal.

[32] F. Cuoco. Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary Prevention , 2012 .

[33] Y. Oade,et al. Arrhythmogenic right ventricular cardiomyopathy , 2011, BMJ Case Reports.

[34] Brian R. Anderson,et al. Genetic Variation in Titin in Arrhythmogenic Right Ventricular Cardiomyopathy–Overlap Syndromes , 2011, Circulation.

[35] P. Elliott,et al. Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy: Impact of Genetics and Revised Task Force Criteria , 2011, Circulation.

[36] L. Mestroni,et al. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. , 2011, European heart journal.

[37] D. Corrado,et al. Controversies in cardiovascular medicine Risk of sports : do we need a pre-participation screening for competitive and leisure athletes ? , 2011 .

[38] G. Thiene,et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmosomal mutations , 2011, European heart journal.

[39] G. Breithardt,et al. Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. , 2011, Journal of the American College of Cardiology.

[40] J. Bates,et al. Circ Arrhythm Electrophysiol , 2011 .

[41] M. Link,et al. Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia , 2010, Circulation.

[42] C. Basso,et al. Pitfalls in the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. , 2010, The American journal of cardiology.

[43] L. Jordaens,et al. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Diagnostic Task Force Criteria: Impact of New Task Force Criteria , 2010, Circulation. Arrhythmia and electrophysiology.

[44] Wojciech Zareba,et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, European heart journal.

[45] John C Chambers,et al. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. , 2010, Annual review of medicine.

[46] J. Moolman-Smook,et al. Clinical features, survival experience, and profile of plakophylin-2 gene mutations in participants of the arrhythmogenic right ventricular cardiomyopathy registry of South Africa. , 2009, Heart rhythm.

[47] G. Guerrero-Serna,et al. Loss of Plakophilin-2 Expression Leads to Decreased Sodium Current and Slower Conduction Velocity in Cultured Cardiac Myocytes , 2009, Circulation research.

[48] G. Marcus,et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. , 2009, Journal of the American College of Cardiology.

[49] F. Marchlinski,et al. Epicardial Substrate and Outcome With Epicardial Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2009, Circulation.

[50] F. Duru,et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a not so rare “disease of the desmosome” with multiple clinical presentations , 2009, Clinical Research in Cardiology.

[51] V. Barrios,et al. Arrhythmogenic right ventricular dysplasia. , 2009, Journal of the American College of Cardiology.

[52] Dudley J Pennell,et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. , 2008, Journal of the American College of Cardiology.

[53] A. Nogami,et al. Changes in the Isolated Delayed Component as an Endpoint of Catheter Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy: Predictor for Long‐Term Success , 2008, Journal of cardiovascular electrophysiology.

[54] Sean Connors,et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. , 2008, American journal of human genetics.

[55] D. Corrado,et al. Three-dimensional electroanatomical voltage mapping and histologic evaluation of myocardial substrate in right ventricular outflow tract tachycardia. , 2008, Journal of the American College of Cardiology.

[56] P. Syrris,et al. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[57] S. Russell,et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[58] S. Peters. Long-term follow-up and risk assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy: personal experience from different primary and tertiary centres , 2007, Journal of cardiovascular medicine.

[59] A novel treatment strategy for therapy refractory ventricular arrhythmias in the setting of arrhythmogenic right ventricular dysplasia. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[60] Petros Syrris,et al. Clinical and Genetic Characterization of Families With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Provides Novel Insights Into Patterns of Disease Expression , 2007, Circulation.

[61] G. Boriani,et al. Outcome of cardioverter–defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy , 2007, Heart and Vessels.

[62] D. Pennell,et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. , 2006, Journal of the American College of Cardiology.

[63] G. Breithardt,et al. Age- and Training-Dependent Development of Arrhythmogenic Right Ventricular Cardiomyopathy in Heterozygous Plakoglobin-Deficient Mice , 2006, Circulation.

[64] Maurizio Schiavon,et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. , 2006, JAMA.

[65] A. Biederman,et al. Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[66] W. Shimizu,et al. Catheter Ablation of Stable and Unstable Ventricular Tachycardias in Patients with Arrhythmogenic Right Ventricular Dysplasia , 2006, Journal of cardiovascular electrophysiology.

[67] D. Corrado,et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. , 2006, Circulation.

[68] S. Russell,et al. Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. , 2005, Heart rhythm.

[69] E. Aliot,et al. Electroanatomic mapping characteristics of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. , 2005, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[70] K. Lemola,et al. Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre , 2005, Heart.

[71] G. Danieli,et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. , 2005, European heart journal.

[72] A. Verma,et al. Short- and Long-Term Success of Substrate-Based Mapping and Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia , 2005, Circulation.

[73] J. Bourke,et al. Right ventricular disarticulation. An 18-year single centre experience. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[74] S. Russell,et al. Arrhythmogenic Right Ventricular Dysplasia: A United States Experience , 2005, Circulation.

[75] A. Bassett,et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). , 2005, Journal of the American College of Cardiology.

[76] Gian Antonio Danieli,et al. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. , 2005, Cardiovascular Research.

[77] S. Sen-Chowdhry,et al. Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. , 2004, The American journal of medicine.

[78] A. Russo,et al. Electroanatomic Substrate and Outcome of Catheter Ablative Therapy for Ventricular Tachycardia in Setting of Right Ventricular Cardiomyopathy , 2004, Circulation.

[79] X. Jouven,et al. Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2004, Circulation.

[80] H. Halperin,et al. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[81] G. Breithardt,et al. Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients , 2004, Circulation.

[82] Paul J. Wang,et al. Arrhythmogenic Right Ventricular Dysplasia: Clinical Results with Implantable Cardioverter Defibrillators , 1997, Journal of Interventional Cardiac Electrophysiology.

[83] M. Link,et al. Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.

[84] Maurizio Schiavon,et al. Does sports activity enhance the risk of sudden death in adolescents and young adults? , 2003, Journal of the American College of Cardiology.

[85] G. Steinbeck,et al. Electroanatomic Mapping of Endocardial Right Ventricular Activation as a Guide for Catheter Ablation in Patients with Arrhythmogenic Right Ventricular Dysplasia , 2003, Pacing and clinical electrophysiology : PACE.